It sounds easy enough to cover GLP-1s for weight loss‚ but the harder policy question is: How much control do you want over how these drugs are used? How much are you willing to pay when members don’t use them the way you would have liked them to?
But the majority of employers find themselves in one of four places: a standard PBM benefit‚ a metabolic program‚ a direct-to-employer deal‚ or some sort of outcomes-based payment․
They’re not interchangeable․
Utilization Control and Plan Flexibility
PBM-run programs and most metabolic programs come with standardized protocols. That’s not necessarily bad, but it does mean the program wasn’t built around your population specifically. Formulary decisions and rebate strategy are driving the design more than your clinical preferences are.
DTE arrangements flip that. Eligibility criteria, clinical requirements, monitoring expectations — employers set those directly rather than inheriting whatever the PBM has already built. For employers who’ve had bad experiences with runaway utilization, that level of control matters.
Tying What You Pay to What Members Actually Do
A lot of benefit leaders want to cover GLP-1s but aren’t willing to write a blank check. Metabolic programs are often designed with this in mind: full coverage for members who stay engaged with coaching, little to nothing for those who don’t show up. DTE models can work similarly: use the designated channel and get full coverage, go outside it and pay more out of pocket.
Outcomes-based payment models take it a step further. You pay the full drug cost only when specific clinical targets are hit. If the vendor or PBM falls short, the payment adjusts. It’s one of the few arrangements in pharmacy benefits that actually puts the other party’s money on the line.
Pharmacy Access
Where members can fill their prescriptions matters more to some organizations than others. Standard PBM coverage typically keeps the pharmacy network broad and members fill where they always have. Outcomes-based and specialized models sometimes narrow that network, which can create friction. The tradeoff is usually better cost visibility and tighter quality controls, but employers need to be honest about how much disruption their population will tolerate.
The Cost Picture: Rebates, Wraparound Costs, and Net Spend
Rebates from PBM-managed programs tend to come back faster because the infrastructure for them already exists. That said, rebate speed is usually a secondary consideration. What matters more is net cost.
Standard PBM coverage tends to carry the highest net drug cost. You’re working off list price with a rebate offset, not a fundamentally different economic structure. DTE arrangements, direct contracting, and outcomes-based models can bring that number down, even when the headline rebate looks smaller.
Where metabolic programs get expensive isn’t the drug; it’s everything around it. Health coaching, nutrition support, behavior change platforms. You’re buying a care model. That’s worth it for some employers and not for others.
How Most Employers Actually Decide
The employers who land on the right model usually start with a clear point of view on what they’re trying to accomplish. Clinical control and cost predictability tend to push toward DTE or outcomes-based arrangements. Preserving member experience and keeping administration simple often keeps employers with their existing PBM. A genuine commitment to long-term behavior change, even at higher short-term cost, points toward metabolic programs.
There’s no universally right answer. But there is usually a wrong one, and it’s picking a model before you’ve decided what you actually stand for.